<DOC>
	<DOCNO>NCT01027871</DOCNO>
	<brief_summary>Comparison fast blood glucose level patient Type 2 diabetes 12 week treatment new basal insulin analog insulin glargine .</brief_summary>
	<brief_title>A Study Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Patients study continue use stable prestudy dose metformin and/or sulfonylurea . Prestudy therapy also include daily insulin glargine NPH insulin . The 12-week active treatment phase follow 4-week follow-up period , patient return basal insulin recommend investigator .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus ( T2DM ) least 1 year At least 18 year age Using metformin and/or sulfonylurea ( ) daily glargine NPH least 3 month prior study . Prestudy dose requirement : insulin dose maximum 1.0 U/kg/day . Oral antihyperglycemic medication ( OAMs ) : Metformin dose least 1500 mg/day and/or sulfonylurea dose least half maximum daily dose specified local package insert . OAM dose stable 6 week prior study . HbA1c le equal 10.5 % randomization BMI 19 45 kg/m2 Capable willing prepare inject insulin syringe continue use prestudy OAMs , monitor blood glucose ; complete study diary ; receptive diabetes education ; comply study visit receive telephone call visit Women childbearing potential must test negative pregnancy receive treatment agree use reliable birth control complete followup visit Longterm use short rapidacting premixed insulin within 6 month study . Shortterm insulin therapy occasional use permit Use glucoselowering medication allow inclusion criterion 3 month entry study Use prescription overthecounter medication promote weight loss within 3 month entry study Current participation weight loss program , plan study Treatment antibodybased therapy within 6 month prior study Use chronic ( &gt; 14 consecutive day ) systemic glucocorticoid therapy currently within 4 week prior study More 1 episode severe hypoglycemia within 6 month prior study , currently diagnose hypoglycemia unawareness 2 emergency room visit hospitalization due poor glucose control 6 month precede study Liver disease History renal transplantation , current renal dialysis , creatinine &gt; 2.0 mg/dL ( 177 Î¼mol/L ) Cardiac disease mark impact physical functioning Clinically significant ECG abnormality screen Malignancy basal cell squamous cell skin cancer Fasting triglycerides &gt; 500 mg/dL Known diabetic autonomic neuropathy Known hypersensitivity allergy study insulin excipients Blood transfusion severe blood loss within 3 month prior entry study know hemoglobinopathy , hemolytic anemia , sickle cell anemia , traits hemoglobin abnormality know interfere HbA1c methodology Irregular sleep/wake cycle Women breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>